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We report 5 cases of disseminated infection caused by 
Blastoschizomyces capitatus yeast in central Switzerland. 
The emergence of this yeast in an area in which it is not 
known to be endemic should alert clinicians caring for 
immunocompromised patients outside the Mediterranean 
region to consider infections caused by unfamiliar fungal 
pathogens. 
In recent years, the frequency of opportunistic fungal infections has increased in parallel with the growing 
number of patients receiving aggressive chemotherapy 
(1,2). Most fungal infections are caused by Candida spp. 
and Aspergillus spp., but reports of infections caused 
by rare molds and unusual yeasts are increasing. The 
widening range of fungal pathogens usually has been 
ascribed to the growing number of immunocompromised 
hosts and the use of antifungal prophylaxis (1,3). Another 
major contributor to the changing epidemiology of 
opportunistic fungal infections may be climatic changes 
(4,5), particularly for organisms for which geographic 
distribution appears to be restricted by climatic factors. 
We report the emergence of disseminated infections 
caused by Blastoschizomyces capitatus in the temperate 
zone of central Switzerland.
B. capitatus, a yeast formerly known as Trichosporon 
 spp. and Geotrichum capitatum, can be isolated from the 
environment and may be a constituent of the microfl ora of 
the skin and the mucosa of the respiratory and digestive 
tracts (6). Colonization of human mucosa may precede 
invasion and hematogenous dissemination, resulting in 
invasive tissue infection of mainly the lung, liver, and 
skin (7–9). The dominant predisposing factor in >90% 
of reported cases is prolonged and profound neutropenia 
in patients with acute leukemia (6,7,9). Infections 
in neutropenic hosts share similarities with invasive 
candidiasis, but with B. capitatus, the rate of recovery 
from the bloodstream (≈80%), frequency of invasive 
tissue infections (≈60%), and rate of death (≈60%) are 
higher (6–9).
Climatic factors seem to play a selective role in the 
epidemiology of infections caused by B. capitatus. The 
geographic distribution of reported cases is restricted; 
most cases (87%) are observed in Europe, particularly in 
the Mediterranean region during the hottest period of the 
year. Italy, Spain, and France report 87% of the cases in 
Europe (7,8). Of the 99 B. capitatus infections reported 
worldwide through 2004, a total of 38 occurred in Italy 
(all but 1 in the central and southern regions), 30 in Spain, 
and 7 in France. Thus, approximately two thirds of all 
cases occurred in locations below 44° northern latitude, 
characterized by a Mediterranean climate with hot, 
dry summers and mild, wet winters. Central European 
countries, which have a temperate climate, contributed 
only 11 cases, and only 13 cases were reported from other 
continents (7). These fi ndings are confi rmed by recent 
data collected by the ARTEMIS DISK Surveillance 
Study, a longitudinal fungal surveillance program 
including Candida and non-Candida spp. yeasts isolated 
globally (10,11). To our knowledge, the only known 
case of invasive blastoschizomycosis in Switzerland was 
reported in 1983 (12).
The Patients
Five patients with B. capitatus infections were 
observed at 3 tertiary care hospitals in Switzerland during 
June 2009–June 2011 (Tables 1, 2). These hospitals provide 
services to a population of ≈3 million persons living in the 
temperate zone north of the Alps in an area ≈5,000 km2. 
A structured chart review was conducted for each patient, 
and further information was obtained from the involved 
infectious diseases specialist. The yeast was identifi ed by 
using standard culture methods (Sabouraud dextrose agar 
with chloramphenicol and gentamicin and corn meal agar 
Tween 80; both from Oxoid, Cambridge, UK) and ID 32 
C (bioMérieux, Marcy l’Etoile, France) (13). Identifi cation 
of isolates was confi rmed by DNA sequence analysis of 
the intergenic spacer (ITS) region (primers ITS1 + ITS4, 
GenBank accession nos. HQ014711.1 and HQ014712.1). 
For antifungal drug susceptibility testing, a microtiter 
broth dilution method based on the Clinical and Laboratory 
Standards Institute M27-A2 standard (Sensititre YeastOne; 
TREK Diagnostic Systems, East Grimstead, UK) was 
performed. Disk diffusion testing of fl uconazole and 
voriconazole was performed as described (10). A review 
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of the microbiology laboratory records of the 5 Swiss 
university centers yielded no additional isolations of B. 
capitatus in the past 5 years.
Patient 1 was a 66-year-old man with secondary acute 
myeloid basophilic leukemia. He became febrile, and 
pulmonary nodules and pustular skin lesions developed 
after induction chemotherapy. Blood cultures and cultures 
from a skin lesion yielded B. capitatus. The patient was 
treated with amphotericin B and voriconazole, both of 
which had low MICs. Skin lesions improved within days, 
and pulmonary nodules resolved within weeks. Eventually, 
relapsing leukemia proved refractory, and the patient died 
of multiorgan failure.
Patient 2 was a 68-year-old woman with acute myeloid 
leukemia. Neutropenic fever developed after induction 
chemotherapy. Blood cultures yielded B. capitatus. She was 
treated with liposomal amphotericin B and voriconazole. 
However, she died of multiorgan failure 9 days after 
diagnosis.
Patient 3 was a 58-year-old man receiving induction 
chemotherapy for acute myeloid leukemia, who was 
treated for polybacterial neutropenic sepsis. Caspofungin 
was added because of persistent fever. B. capitatus was 
isolated from blood cultures, urine, and tracheobronchial 
fl uid while he was being treated. Antifungal therapy was 
switched to liposomal amphotericin B and voriconazole. 
When a preliminary report indicated an amphotericin 
B MIC >2 μg/mL (Etest; bioMérieux) for the isolate, 
treatment was changed to fl uconazole. Multiorgan failure 
occurred, and he died 15 days after diagnosis. Autopsy 
fi ndings confi rmed extensive fungal pulmonary infi ltrates 
with angioinvasion and multiple foci of B. capitatus 
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Table 1. Clinical characteristics of 5 patients with Blastoschizomyces capitatus yeast infection, Switzerland, June 2009–June 2010* 
Patient no. 1 2 3 4 5 
Age, y/sex 66/M 68/F 58/M 60/M 56/F 
Underlying disease AML AML AML CAPD for renal 
failure after renal 
transplant 
Diabetes mellitus, 
renal/pancreas
transplant 
Immunosuppression Induction 
chemotherapy; 
reinduction 2?
Induction
chemotherapy
Induction
chemotherapy 
CAPD;
CycA, PDN 
Tacrolimus, 
mycophenolate, PDN, 
thymoglobuline 
Galactomannan assay  Negative Negative BAL positive; 
serum not done 
Not done Negative 
Day of chemotherapy 
cycle at first isolation 
14 13 22 NA NA 
Neutrophil count at 
diagnosis, ? 109 l–1
<0.1 <0.1 0.25 7.49 4.74 
Days of neutropenia at 
diagnosis
16 8 18 NA NA 
Days of persistent 
fungemia/funguria 
6 4 3 NA 114 
Sites involved clinically Lungs, skin, liver, 
spleen, brain 
Lungs Lungs, brain Peritoneal fluid Bladder, right kidney 
Isolation of B. capitatus Blood, skin Blood Blood, urine, DTA Peritoneal fluid, 
peritoneal dialysis 
catheter, deep 
tissue biopsy 
Urine 
Sequential treatment after 
isolation (duration, d) 
1. L-AMB (7) 1. L-AMB (2) 1. L-AMB (1) 1. VRC (28) 1. VRC (17) 
2. L-AMB + VRC (8) 2. VRC (3) 2. L-AMB + VRC (1)  2. FLC (8) 
 3. L-AMB (25)  3. FLC (11)  3. AMB (4) 
 4. VRC (145)    4. VRC (110, ongoing)
Days from collection of first 
positive sample to start of 
adequate treatment 
0 1 3 4 3 
Outcome (cause of death) Death 185 d after 
diagnosis (relapsing 
leukemia and MOF) 
Death 9 d 
after diagnosis 
(MOF) 
Death 15 d after 
diagnosis (MOF) 
Alive Alive 
Contribution of B. capitatus
to death 
– + + NA NA 
Travel history during 
previous year 
Trip to southern 
France 3 months 
before diagnosis 
None Unknown None None 
*Diagnosis is defined as the day of collection of first sample positive for B. capitatus. No patients received antifungal prophylaxis. AML, acute myeloid 
leukemia; CAPD, continuous ambulatory peritoneal dialysis; CycA, cyclosporine A; PDN, prednisone; BAL, bronchoalveolar lavage; NA, not applicable; 
DTA, deep tracheal aspiration; L-AMB, liposomal amphotericin B; VRC, voriconazole; FLC, fluconazole; AMB, deoxycholate amphotericin B; MOF, 
multiorgan failure.  
infection in the liver, spleen, kidneys, bone marrow, 
myocardium, and brain.
Patient 4 was a 60-year-old man who was receiving 
continuous ambulatory peritoneal dialysis for renal 
failure 15 years after kidney transplantation for chronic 
glomerulonephritis; he sought care for acute peritonitis. 
Upon cultivation of yeasts in the dialysis fl uid, caspofungin 
was started and changed to voriconazole when B. capitatus 
was identifi ed. The patient’s symptoms rapidly improved, 
and voriconazole was discontinued after 4 weeks.
Patient 5 was a 56-year-old woman who underwent 
combined pancreas–kidney transplantation because 
of diabetic nephropathy and pancreatic insuffi ciency 
in December 2010. Two months later, B. capitatus 
was cultivated in urine while she was being treated 
empirically with caspofungin for possible fungal infection. 
Emphysematous cystitis was detected by computed 
tomographic scan, and B. capitatus was cultured from 
urine collected from the right kidney. Despite treatment 
with voriconazole, B. capitatus was cultured from urine for 
several weeks; however, the patient recovered.
Conclusions
The repeated isolation of B. capitatus in a temperate 
climate zone was unexpected because of the well-
documented restriction of B. capitatus to areas with a 
Mediterranean climate >450 km south in Italy, Spain, and 
France. Because of the high recovery rate of the organism 
from blood cultures of patients with disseminated infection 
and the ease of culturing B. capitatus on standard media, 
we believe it unlikely that a large number of cases could 
have been missed in the past.
Central Switzerland has witnessed a steady rise 
in temperatures since the mid-1980s. Mean annual 
temperatures for the past 25 years were all above the mean 
for 1961–1990 and now exceed those of 1980 by >1°C. The 
rise in average temperatures was more pronounced during 
spring and summer months. Since 1981, average spring and 
summer temperatures in central Switzerland have increased 
by 0.77°C and 0.48°C per decade, respectively (14).
The occurrence of 4 of the 5 infections reported 
here during the warm season indicates that the rising 
temperatures might have contributed to the expanded range 
of climatically restricted fungi to cooler areas and that 
the emergence of B. capitatus might be a consequence of 
the local effects of global warming (5,15). Alternatively, 
importation of the pathogen from areas to which it is 
endemic through increasing traffi c of humans and goods 
might have led to establishment of a new endemic hotspot. 
Our observation should alert clinicians caring for severely 
immunocompromised patients in temperate areas to 
consider infections caused by unfamiliar fungal pathogens, 
notably B. capitatus. 
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